We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
01 Mar 2023 - 03 Mar 2023

First-in-Class AI Diagnostic Solutions Improve Patient Outcomes in Breast Cancer and Colorectal Cancer

By LabMedica International staff writers
Posted on 06 Sep 2022
Print article
Image: Owkin’s AI diagnostic solutions for breast cancer and colorectal cancer have been approved for use in Europe (Photo courtesy of Owkin)
Image: Owkin’s AI diagnostic solutions for breast cancer and colorectal cancer have been approved for use in Europe (Photo courtesy of Owkin)

Two first-in-class rapid, affordable AI-based diagnostic solutions that are designed to improve outcomes for patients with breast cancer and colorectal cancer have been approved for use in Europe. By using AI to analyze digital pathology images, they are designed to help clinicians make precision medicine – diagnostic and treatment based on a patient's individual characteristics – more accessible to more patients at an earlier stage of their disease.

Owkin Dx RlapsRisk BC and Owkin Dx MSIntuit CRC from Owkin (New York, NY, USA) have received CE-IVD approval for diagnostic use in the European Union. RlapsRisk BC is the first CE-IVD approved digital pathology-based AI diagnostic that predicts the risk that early breast cancer patients will relapse. MSIntuit CRC is the first CE-IVD approved AI solution that enables the identification of microsatellite stable (MSS) patients from routine histology slides, enabling a significant reduction in time and the number of diagnostic tests for detecting MSI in clinical practice.

RlapsRisk BC is an AI prognostic solution that predicts whether a breast cancer patient (ER+/HER2-) will go on to relapse after treatment, informing oncologists which high-risk patients may benefit from targeted therapies and which low-risk patients could potentially avoid chemotherapy. The solution aims to revolutionize breast cancer care management by using AI to assess the risk of relapse after treatment from digital images of tissue samples. Currently, breast cancer patients at risk of relapse are identified through expensive, time-consuming molecular or genetic testing. RlapsRisk BC offers doctors a way to identify patients at risk of relapsing by using AI on digital pathology data that will already be held on nearly all breast cancer patients in around 15 minutes.

MSIntuit CRC is an AI digital pathology diagnostic solution that pre-screens for a biomarker in colorectal cancer tumors known as microsatellite instability (MSI) – a defect in a cell’s ability to correct mistakes that occur when DNA is copied. The diagnostic solution rules out MSS phenotypes, allowing pathologists to concentrate their resources on confirming those patients who exhibit MSI. By using an AI model to analyze digital images of tissue samples, doctors are able to more efficiently screen patients when compared to standard testing techniques, which include time and patient tissue sample-consuming polymerase chain reaction (PCR) testing or immunohistochemistry.

“Owkin's RlapsRisk BC enables pathologists to provide oncologists and patients with insights on the risk of relapse, crucial information for the treatment decision-making to avoid unnecessary chemotherapy. Thanks to RlapsRisk, HER2-, ER+ patients will benefit from an automated and accurate prognosis test using just a simple, standard-stained tumor slide,” said Dr. Magali Lacroix-Triki, MD, PhD, an expert breast pathologist at the Department of Medical Biology and Pathology, Institut Gustave Roussy. “AI-based digital pathology diagnostics could help us to provide a comprehensive analysis of each tumor from just one representative standard-stained tumor slide, in a complementary process to the pathologist’ diagnosis. This would democratize access to precision medicine, unlocking a new era of treatment for patients across the world.”

“As colorectal cancer is the third most common cancer in the world, it is crucial that we are able to screen patients for biomarkers that make them eligible for potentially lifesaving treatments. dMMR/MSI screening should be performed on all colorectal cancer patients, but pathologists' time and resources are often too stretched,” said Professor Magali Svrcek, MD, PhD, Sorbonne Université, AP-HP, Saint-Antoine Hospital, Department of Pathology. “Owkin's new AI diagnostic solution MSIntuit CRC will roughly half the number of cases requiring screening. It is designed to help more patients receive treatment sooner. AI-based digital pathology algorithms like these, developed in consultation with pathologists, will soon become an integral part of our daily practice. They will help patients to benefit from the best treatment for them sooner – a new era of personalized medicine.”

Related Links:

Gold Supplier
Group A Streptococcus Antigen Test
OSOM Strep A Test
3-Part Auto Hematology Analyzer
Auto Mass Spectrometry Microbial Identification System
Microbe LW MS-5000
Total Immunoglobulin E (IgE) Test
ALLERgen Total-IgE ELISA Kit

Print article



view channel
Image: Scientists have won USD 9.5 million to study emerging pathogens (Photo courtesy of Pexels)

Study of Emerging Pathogens to Better Understand Influenza-Antibody Interactions Could Improve Diagnostics

Outbreaks of Avian influenza have occurred around the world for over a century. The highly pathogenic H5N1 virus which was first identified in 1996 can lead to severe disease and has a high fatality rate... Read more


view channel
Image: Medical illustration of Carbapenem-resistant Enterobacteriacea (Photo courtesy of CDC, Stephanie Rossow)

Breakthrough Test Enables Targeted Antibiotic Therapy for Various Enterobacter Species

Bacteria of the Enterobacter genus are considered to be the most dangerous bacteria linked to hospital infections across the world. Some of their representatives demonstrate high resistance to commonly-used... Read more


view channel
Image: Flexible copper sensor made cheaply from ordinary materials (Photo courtesy of University of São Paulo)

Low-Cost Portable Sensor Detects Heavy Metals in Sweat

Heavy metals like lead and cadmium can be found in batteries, cosmetics, food and many other things that have become a part of daily life. However, they become toxic if they accumulate in the human body... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.